NCT06004674RecruitingPhase 2
Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project
Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project (UPPPP Trial)
Source: ClinicalTrials.gov · Last updated 23 Jul 2026
Brief summary (registry, in English)
The goal of this randomized clinical trial is to evaluate if we can use placental pathology in a prior pregnancy which had an adverse outcome, such as early delivery, stillbirth, a baby born smaller than expected, or severe forms of high blood pressure during pregnancy, to guide treatment in the subsequent pregnancy and reduce risk of recurrent adverse pregnancy events. The main questions it aims to answer are: * Whether enoxaparin prevents recurrent adverse pregnancy outcomes among patients with a prior adverse pregnancy outcome that occurred in the setting of maternal vascular malperfusion (MVM). * If enoxaparin reduces the occurrence or severity of MVM among patients with a prior adverse pregnancy outcome that occurred in the setting of MVM.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 8 Aug 2023
- Start date
- 26 Dec 2023
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Endeavor Health
- NCT number
- NCT06004674
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 20
- From 26 Dec 2023 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects with mechanical prosthetic heart valves
Lab values
- Contraindication to enoxaparin: Specifically active major bleeding, known thrombocytopenia (platelets \<100), hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol
- Chronic kidney disease with eGFR\< 60
- Known chronic liver disease with baseline AST/ALT \> 3 x upper limit of normal
Other
- Anticoagulation planned for current pregnancy (including warfarin, enoxaparin, heparin)
- Known major fetal anomaly
Criteria the registry did not label
- Eligibility Criteria:
- Inclusion (must meet all three criteria):
- Subjects with a prior adverse outcome in a prior pregnancy. Adverse outcome is defined as prior singleton preterm birth ( \< 37 weeks), SGA infant (defined as birthweight \< 10th percentile), preeclampsia with severe features, or stillbirth (fetal demise after 20 weeks gestation), as certified by an obstetrician
- Patients with maternal vascular malperfusion on pathology from pregnancy with prior adverse pregnancy outcome, as certified by a perinatal placental pathologist
- Current singleton pregnancy at \<16 6/7 weeks gestational age.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NorthShore University HealthSystem Coordinator of this site? Confirm its status | Evanston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.